By Wesley C. Sassaman, DNP, MPH, MSN-NE, MBA, FNP-C, CARN-AP
Introduction
Parents should be aware that methamphetamine is a highly popular stimulant drug among teens and young adults, posing significant risks due to its addictive nature. Methamphetamine addiction is a serious concern for many parents, as this powerful stimulant significantly alters brain function, particularly affecting the systems responsible for mood and reward. Understanding how methamphetamine impacts these critical areas can illuminate why it is so addictive and challenging to overcome. As a parent, being informed about the signs and effects of methamphetamine use is crucial for making informed decisions about your child's care and recovery. Look up "Super Meth".
By posting this blog, I aim to help parents gain insights into the nature of methamphetamine addiction, enabling them to better support their child on their journey to recovery and ensure they receive the necessary help. Understanding this addiction is essential in providing the right support and making informed decisions for their child's well-being.
Brain Areas Affected by Methamphetamine
Nucleus Accumbens and Ventral Bed Nucleus of the Stria Terminalis (vBNST): METH significantly enhances dopamine (DA) and norepinephrine (NE) transmission in these limbic structures, which are critical for reward processing and addiction. The increase in DA and NE concentrations is dose-dependent, with higher doses leading to more pronounced effects (Bhimani et al., 2023).
Dorsomedial Striatum (DMS): METH alters the intrinsic excitability of spiny projection neurons in the DMS, which is involved in goal-directed behaviors. This alteration is specific to the indirect pathway neurons and varies with the duration of abstinence, indicating a complex role in addiction and relapse (Choi et al., 2022).
Cerebellum and Frontoparietal Network: METH use disorder is associated with increased functional connectivity within the cerebellum and decreased connectivity in the frontoparietal network (Prefrontal cortex and parietal cortex). The frontoparietal network is a key brain network involved in various cognitive functions, including attention, working memory, and executive control. The prefrontal cortex, including areas like the dorsolateral prefrontal cortex, is essential for executive functions and decision-making.
Meanwhile, the parietal cortex, particularly the posterior parietal cortex, plays a crucial role in managing spatial attention and integrating sensory information. Together, these brain regions support complex cognitive processes, enabling flexible thinking and effective problem-solving. However, when there are disruptions in these areas, it may contribute to impulsivity and impaired cognitive control, as noted by recent studies. Understanding these functions can provide valuable insights into cognitive health and behavior (Luo et al. ,2024).
Prefrontal Cortex and Hippocampus: High doses of METH induce synaptic degeneration and neuronal loss in these areas, which are crucial for decision-making and memory. Conversely, low doses may promote synaptic plasticity, highlighting dose-dependent effects on brain structure (Ding et al., 2022).
Mechanisms of Addiction
Dopamine and Norepinephrine Dysregulation: METH's ability to increase DA and NE levels in key brain regions underlies its addictive potential. The differential regulation of these neurotransmitters by METH isomers (dextromethamphetamine vs levomethamphetamine) suggests distinct pathways contributing to its addictive properties (Bhimani et al., 2023).
Neuroplasticity and Synaptic Changes: METH induces structural changes in synapses, affecting both presynaptic and postsynaptic morphology. These changes are dose-dependent and can lead to neurodegeneration or enhanced synaptic connectivity, influencing addiction and recovery processes (Ding et al., 2022).
Craving and Impulsivity: Craving is a central feature of METH addiction, with specific electroencephalographic patterns predicting craving intensity. Impulsivity, linked to altered brain connectivity and regional homogeneity, further complicates addiction management (Tian et al., 2023; Zhou et al., 2022).
Relative Addictiveness of Methamphetamine
METH is considered highly addictive, often compared to other potent stimulants like cocaine. Its rapid and intense effects on the brain's reward system make it more addictive than many other substances. The prevalence of METH use among specific populations, such as men who have sex with men, underscores its widespread addictive potential and the need for targeted interventions (Lodge et al., 2023).
While METH is highly addictive, its effects and the degree of addiction can vary based on individual differences, dosage, and frequency of use. The neurobiological mechanisms underlying METH addiction are complex and involve multiple brain regions and neurotransmitter systems. Understanding these mechanisms is crucial for developing effective treatments and interventions for METH use disorder.
Potential Treatment Medications
Methamphetamine addiction presents a significant challenge due to the severe withdrawal symptoms experienced by individuals attempting to quit. While no medication is officially approved for methamphetamine withdrawal, several pharmacological treatments have shown promise in reducing withdrawal severity and cravings. I’m crafting this blog to synthesize findings from recent studies to highlight potential medications that could be used to alleviate methamphetamine withdrawal symptoms.
Lisdexamfetamine
Lisdexamfetamine, commonly used for attention deficit hyperactivity disorder, has been explored as a treatment for methamphetamine withdrawal. A pilot study demonstrated that a tapering dose of lisdexamfetamine was both safe and feasible for treating acute methamphetamine withdrawal in an inpatient setting. Participants reported reduced withdrawal severity and cravings, with high treatment satisfaction and no serious adverse events (Acheson, et al., 2022; Acheson, et al., 2022).
Modafinil
Modafinil, a wakefulness-promoting agent, has been evaluated for its efficacy in methamphetamine dependence. A randomized controlled trial found that modafinil significantly reduced relapse rates and cravings compared to a control group. Patients receiving modafinil also showed improved retention rates and negative urine drug screens, indicating its potential effectiveness in managing withdrawal symptoms (Tavakkoli Fard, et al., 2020).
Bupropion and Naltrexone
The combination of extended-release bupropion and naltrexone has been studied in a multicenter, double-blind trial. This combination was shown to reduce methamphetamine use and cravings, with a significant number of participants achieving meth-negative urine samples. However, the treatment was associated with some adverse events, such as nausea and dizziness, which need to be considered (Marshall, & Reese, 2023).
Methylphenidate
Methylphenidate, another stimulant medication, has been investigated for its effects on methamphetamine withdrawal. Studies indicate that methylphenidate can significantly reduce cravings and improve mental health outcomes when combined with behavioral therapies like the Matrix Model. This combination was more effective than either treatment alone, suggesting a synergistic effect (Aryan, et al., 2020; Ahmadi, 2015).
N-acetylcysteine (NAC)
NAC, known for its role in restoring glutamate homeostasis, has shown promise in reducing cravings and improving mental health in methamphetamine-dependent individuals. A clinical trial demonstrated that NAC significantly reduced addiction severity and depression scores compared to placebo, with a higher success rate in maintaining abstinence (Karami, et al. 2020).
Candesartan
Candesartan, an angiotensin-II receptor blocker, reduces the rewarding effects of methamphetamine through several mechanisms, including modulation of the renin-angiotensin system, reduction of oxidative stress, and potential interactions with dopamine pathways. By inhibiting the angiotensin II receptor subtype 1, candesartan increases levels of angiotensin-converting enzyme 2 (ACE2) in the kidneys, which may influence blood pressure and drug reward (Wang et al. 2024). Additionally, its ability to lower oxidative stress and inflammation may indirectly affect methamphetamine's rewarding properties, given the known link between oxidative stress and addiction (Sakti et al. 2023; Lee et al. 2023). While direct evidence of candesartan's impact on dopamine pathways is limited, similar compounds have been shown to interact with dopamine receptors, suggesting a possible role in modulating drug reward (Mohammadi et al. 2023).
While these medications show potential, it is important to note that the evidence supporting their use is still emerging, and further research is needed to establish their efficacy and safety comprehensively. Additionally, the development of vaccines targeting methamphetamine addiction is being explored as a novel approach to reduce misuse and withdrawal symptoms, offering a potential alternative to pharmacotherapy (Lu et al. 2024)].
Common Withdrawals Symptoms
Methamphetamine withdrawal is characterized by a range of physical and psychological symptoms that can vary in intensity and duration. These symptoms are primarily due to the drug's impact on the central nervous system and immune system, and they can significantly affect the quality of life of individuals undergoing withdrawal. The following sections detail the common symptoms associated with methamphetamine withdrawal, supported by recent research findings.
Psychological Symptoms
Anxiety and Depression: Anxiety-like symptoms are prevalent during the acute withdrawal phase of methamphetamine use. These symptoms are linked to increased microglial activation and neuroinflammation in the brain, particularly in the striatum and hippocampus (Re et al., 2022). Depression is also a common symptom, often exacerbated by the dysregulation of neurotransmitters and inflammatory responses (Wu et al., 2022).
Cravings and Mood Swings: Intense cravings for methamphetamine and mood swings are frequently reported during withdrawal. These symptoms are driven by the brain's altered reward pathways and can persist for extended periods, contributing to the high relapse rates (Wu et al., 2022).
Physical Symptoms
Fatigue and Sleep Disturbances: Individuals often experience extreme fatigue and sleep disturbances, including insomnia or hypersomnia, during withdrawal. These symptoms are attributed to the body's attempt to rebalance after the stimulant effects of methamphetamine (Wu et al., 2022).
Increased Appetite: A marked increase in appetite is commonly observed, which contrasts with the appetite suppression experienced during active methamphetamine use (Wu et al., 2022).
Immune System Alterations
Cytokine Imbalance: Methamphetamine withdrawal is associated with significant changes in cytokine levels, including increased levels of IL-6, IL-7, and IL-12p70, which persist even after prolonged abstinence. These changes reflect ongoing immune system dysregulation (Wu et al., 2022).
Peripheral Immune Dysfunction: Acute withdrawal is characterized by a decrease in CD3+T and CD4+T cell numbers, which are restored during protracted withdrawal, indicating a temporary immune suppression (Wu et al., (2022).
While the symptoms of methamphetamine withdrawal are well-documented, it is important to consider the broader context of substance withdrawal syndromes. For instance, withdrawal from other substances like cannabis and anabolic steroids also involves a complex interplay of psychological and physical symptoms, highlighting the need for comprehensive treatment approaches tailored to each substance's unique withdrawal profile (Sharma et al.,2023; Sharma et al., 2022).
Conclusion
In conclusion, understanding methamphetamine addiction is crucial for parents navigating the challenging journey of supporting their child's recovery. Methamphetamine significantly impacts brain function, affecting areas responsible for mood, reward, decision-making, and cognitive control. Recognizing the signs and symptoms of methamphetamine use and withdrawal, such as anxiety, cravings, fatigue, and mood swings, is essential for providing timely and effective support.
Potential treatments, while still emerging, offer hope in managing withdrawal and aiding recovery. Medications like lisdexamfetamine, modafinil, and others have shown promise in reducing cravings and withdrawal severity, though further research is needed to confirm their efficacy and safety. Parents play a pivotal role in their child's recovery by staying informed about these treatments and being proactive in seeking professional help.
The path to recovery is complex and requires patience, understanding, and a comprehensive approach. By staying informed and vigilant, parents can make informed decisions that promote their child's well-being and support them through the challenges of overcoming methamphetamine addiction. Reaching out to healthcare providers, support groups, and utilizing available resources can greatly assist in this process, ensuring that children receive the best possible care and support on their road to recovery.
I am hopeful that this blog post will help parents save their teen or young adult from the horrors of this illicit drug, guiding them towards a brighter, healthier future.
References
Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A., Brett, J., Rodgers, C., Gill, A. J., Christmass, M., McKetin, R., Farrell, M., Shoptaw, S., & Siefried, K. J. (2022). Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Drug and Alcohol Dependence, 241, Article 109692.
Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A., Brett, J., Rodgers, C., Gill, A. J., Christmass, M., McKetin, R., Farrell, M., Shoptaw, S., & Siefried, K. J. (2022). Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal. PLOS ONE, 17(10), Article e0275371. https://doi.org/10.1371/journal.pone.0275371
Ahmadi, J. (2015). Methylphenidate in the Treatment of Methamphetamine Withdrawal Craving: A Novel Outcome. iMedPub, 2(1).
Aryan, N., Banafshe, H. R., Farnia, V., Shakeri, J., Alikhani, M., Rahimi, H., Sehat, M., Mamsharifi, P., Ghaderi, A., & Omidi, A. (2020). The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder. Substance Abuse Treatment, Prevention, and Policy, 15(1), 1-9.
Karami, F., Assarian, F., Ghoreishi, F. S., & Sehat, M. (2020). The Efficacy of N-acetylcysteine for the Treatment of Methamphetamine-addicted Patients Under Methadone Therapy: A Double-blind Clinical Trial. Iranian Red Crescent Medical Journal, 22(7).
Lee, J., Jung, Y., Jung, Y. S., Seo, S.-Y., Hong, J. H., Hong, I.-S., Lee, D. H., Kim, O.-H., & Oh, B.-C. (2023). Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation. Experimental and Molecular Medicine, 55(5), 910-925. https://doi.org/10.1038/s12276-023-00789-5
Lu, T., Li, X., Zheng, W., Kuang, C., Wu, B., Liu, X.-X., Xue, Y., Shi, J., Lu, L., & Han, Y. (2024). Vaccines to treat substance use disorders: Current status and future directions. Pharmaceutics. https://doi.org/10.3390/pharmaceutics16010001.
Marshall, B., & Reese, T. (2023). Giving methamphetamine treatment a shot in the arm: Bupropion and naltrexone in methamphetamine use disorder. Evidence-Based Practice.
Mohammadi, M., Eskandari, K., Azizbeigi, R., & Haghparast, A. (2023). The inhibitory effect of cannabidiol on the rewarding properties of methamphetamine is partly mediated by interacting with the hippocampal D1-like dopamine receptors. Progress in Neuro-psychopharmacology & Biological Psychiatry, 126, 110778. https://doi.org/10.1016/j.pnpbp.2023.110778.
Re, G., Li, H., Yang, J., Li, Y., Zhang, Z., Wu, X., Zhou, R., Kong, D., Luo, H., Kuang, Y., & Wang, K. (2022). Exercise modulates central and peripheral inflammatory responses and ameliorates methamphetamine-induced anxiety-like symptoms in mice. Frontiers in Molecular Neuroscience, 15.
Sakti, P. T., Samsu, N. Z., & Rifai, A. (2023). Effects of candesartan compared to losartan on inhibiting mesangial expansion in diabetic model rats receiving rosmarinic acid. Nephrology Dialysis Transplantation, 38(Supplement_1). https://doi.org/10.1093/ndt/gfx123.
Sharma, A., Grant, B. G., Islam, H., Kapoor, A., Pradeep, A. S., & Jayasena, C. N. (2022). Common symptoms associated with usage and cessation of anabolic androgenic steroids in men. Best Practice & Research Clinical Endocrinology & Metabolism, 36(5), 101691-101691.
Sharma, R., Tikka, S. K., Bhute, A. R., Dhamija, P., & Bastia, B. K. (2023). Characterization of cannabis withdrawal symptoms and serum levels of neurotransmitters among cannabis-dependent smokers during sustained abstinence within a controlled residential environment. European Psychiatry, 66, S569-S569.
Tavakkoli Fard, M., Mansouri, S. S., Jafari, A., & Vousooghi, N. (2020). Role of modafinil in the treatment of patients with methamphetamine dependence: An update on randomized, controlled clinical trial. Tropical Journal of Pharmaceutical Research, 19(10), 2179-2185. https://doi.org/10.4314/tjpr.v19i10.28
Wang, P., Ren, Z., Wang, W., Liu, M., Jia, Y., Zhang, M., Xue, Y., Zhang, C., Xu, J., Wang, C., & Wang, X. (2024). Candesartan upregulates angiotensin-converting enzyme 2 in kidneys of male animals by decreased ubiquitination. The FASEB Journal, 38(6), e23537. https://doi.org/10.1096/fasebj.e23537.
Wu, H., Zhang, Z., Ma, Y., Chen, F., Xiong, P., Xie, Z., Ding, G., Yu, J., & Wang, K. (2022). Dynamic immune and exosome transcriptomic responses in patients undergoing psychostimulant methamphetamine withdrawal. Frontiers in Cellular Neuroscience, 16.
Comments